| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1020: Eplontersen for treating hereditary transthyretin-related amyloidosis |
|
Medicine details |
|
| Medicine name | eplontersen (Wainzua®) |
| Formulation | 45 mg solution for injection in pre-filled pens |
| Reference number | 5344 |
| Indication | For treating hereditary transthyretin-related amyloidosis |
| Company | AstraZeneca AB |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/10/24 |
| NICE guidance | TA1020: Eplontersen for treating hereditary transthyretin-related amyloidosis |